Drug updated on 1/29/2024
|Tablet (oral; 3 mg, 4 mg, 5 mg)
|Ongoing and Completed Studies
- Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Product Monograph / Prescribing Information
|Balversa (erdafitinib) Prescribing Information.
|Janssen Products, LP, Horsham, PA
Systematic Reviews / Meta-Analyses
|Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: a systematic review and meta-analysis.
|Frontiers in Oncology
|Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.
|Urologic Oncology: Seminars and Original Investigations
Clinical Practice Guidelines
|Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
|Annals of Oncology
|Bladder cancer, version 3.2020
|Journal of the National Comprehensive Cancer Network